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Ovarian cancerAbstract Benzothiazole moieties substituted with various functional groups were utilized to link
with the isoquinoline alkaloid berberine through a pentyl side chain. Entitled analogs were screened
for antioxidant potency using the DPPH and ABTS bioassays and for their in vitro anticancer activ-
ities against HeLa, CaSki (cervical cancer), and SK-OV-3 (ovarian cancer) cell lines using the SRB
bioassay. The compounds were evaluated for their toxicity to the Madin–Darby canine kidney
(MDCK) cell line. The final compounds demonstrated significant antioxidant potency with IC50
levels of 13.03–24.50 lg/mL and 4.958–7.570 lg/mL in the DPPH and ABTS radical scavenging
bioassays, respectively. The 5e analog with a methoxy functional group and the 5m analog with
a cyano functional group had the most significant DPPH and ABTS radical scavenging activities,
respectively. Moreover, the 5m cyano-based analog had the highest potency against all cancer cell
lines, with IC50 levels of 5.474, 5.311, and 32.61 lg/mL against the HeLa, CaSki, and SK-OV-3 cell
lines, respectively. All the synthesized compounds were characterized by IR, 1H NMR, 13C NMR
spectroscopy and elemental analysis.
 2015 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).guk-ro,
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Bioactive berberine-benzothiazole moieties 2111. Introduction
Diseases, such as diabetes, cirrhosis, cancer, and cardiovas-
cular defects, are associated with the presence of free radi-
cals [1,2]. Bioorganic redox reactions occurring in the
human body introduce free radicals that produce oxidative
damage to lipids, proteins, and nucleic acids [3]. Such oxida-
tive damage can form mutations, causing several types of
cancers. Hence, free radicals often harm the primary
building blocks of human cells which create the seed for
illnesses, such as cancers, hypertension, cardiac infarction,
arteriosclerosis, and cataracts [4]. Homeostasis between free
radicals and antioxidants is necessary for functioning, as
oxidative stress arises if free radicals overcome the body’s
defenses.
Free radicals negatively modify lipids, proteins, and DNA
and induce particular illnesses. Hence, applying an external
source of antioxidants can help cope with this oxidative
stress. Therefore, treatments for these pathophysiological
conditions could benefit from the use of drugs that combine
antioxidant and anti-inflammatory activities. Antioxidants
are natural or synthetic molecules that defend against free
radicals [5]. Thus, they can reverse illnesses, such as
atherogenesis, carcinogenesis, inflammation, and aging [6,7].
Natural products have been an efficient source for the devel-
opment of new medicines. Some new products are in clinical
trials, particularly as anti-cancer and anti-infective agents.
More than 80% of drugs were natural products or inspired
by a natural compound [8]. Over 100 naturally derived
substances are currently in clinical trials, and at least 100
are in preclinical development [9]. Most of these substances
originated from plants and microbial sources [10]. Plant-
based techniques play a significant role in healthcare [11].
The World Health Organization (WHO) estimated that
about 65% of the world’s population depended on plant-
derived traditional medicines for primary medical care in
1985 [12].
Berberine is an isoquinoline alkaloid having a long history
of therapeutic use in Ayurvedic and Chinese medicine. It
occurs in the roots, rhizomes, and stem bark of Hydrastis
canadensis (Goldenseal), Coptis chinensis (Coptis or golden-
thread), Berberis aquifolium (Oregon grape), Berberis vulgaris
(barberry), and Berberis aristata (tree turmeric). Berberine
has significant activities against viruses, protozoans, fungi,
and abdominal viruses. It is also helpful to treat microbial
diarrhea, inflammation, thrombo-cytopenia, ventricular tach-
yarrhythmia, ocular trachoma infections, and sudden coronary
death after ischemic myocardial damage [13]. Berberine also
has important anticancer properties in human malignant brain
tumors, esophageal cancer, and leukemic and colon cancers
[14]. We attached a benzothiazole moiety to the berberine moi-
ety to create semi-synthetic types of berberine. Benzothiazoles
are heterocyclic compounds with various biological activities
[15–21].
Considering the benefits of these heterocyclic nuclei, ber-
berine and substituted benzothiazole moieties in a single
molecular framework are candidate compounds to screen for
biological activity. Thus, in this study, we report that this nat-
ural product skeleton can be used to develop novel agents with
anticancer and antioxidant effects.2. Experimental section
2.1. Materials and methods
The highest quality chemicals and reagents were used in this
study without further purification. The VMP-D open capillary
electronic apparatus (Veego Instruments) was utilized to
obtain the uncorrected melting points of the synthesized
compounds. A Shimadzu 8400-S Fourier-transform infrared
(FT-IR) spectrophotometer (KBr pellets; Tokyo, Japan) and
a Varian 500 MHz model spectrometer (Palo Alto, CA,
USA) (CDCl3 as the solvent and TMS as the internal
standard) were used to obtain 1H nuclear magnetic resonance
(NMR) and 13C NMR spectra of the title compounds.
Thin-layer chromatography (TLC) was carried out using
appropriate mobile phase systems and silica gel-G coated
microscopic glass slides (2  7.5 cm), and the TLC spots were
observed in a UV light chamber. FT-IR bands were presented
in cm1, and the 1H NMR spectral results were furnished in
ppm downfield from TMS with s, singlet; d, doublet; m,
multiplet and br s, broad singlet patterns. Elemental analyzes
(C, H, and N) were performed using a Heraeus Carlo Erba
1180 CHN analyzer (Hanau, Germany).
2.2. General procedure for the synthesis of berberrubine (2)
Berberine chloride (10 g, 0.01 mol) was heated to 190 C for
40 min under reduced pressure (20–30 mmHg) using an oil
pump. The vacuum pump was turned off after the temperature
dropped to room temperature to give a dark brown product.
The product was purified by silica gel column chromatography
(CHCl3/CH3OH:15:1 and 10:1, eluting until no compound was
detected in the eluent) to obtain a brownish red amorphous
powder compound 2 (8.5 g, 85%).
2.3. Synthesis of bromopentylberberrubine (3)
A solution of 2 (5 g, 0.01 mol) and 1,5-dibromopentan
(0.01 mol) in dry acetonitrile was warmed at reflux tempera-
ture for 6 h and then diethyl ether was added. The resulting
solid was filtered and then subject to anion-exchange into
chloride form to give compound 3. Yield: 61%, m.p.
195–197 C; IR (KBr) cm1: 3065, 1615, 1565, 1115–1050
(C–O–C); 1H NMR (CDCl3, 500 MHz): d 9.86 (s, 1H, H-8),
8.49 (s, 1H, H-13), 7.86 (s, 1H, H-1), 7.54 (s, 1H, H-12), 7.54
(s, 1H, H-4), 6.84 (s, 1H, H-11), 6.03 (s, 2H, –OCH2O), 4.93
(t, 2H, J= 6.3, H-6), 4.35 (t, 2H, J= 6.5, H-15), 4.03
(s, 3H, –OCH3), 3.19 (t, 2H, J= 6.4, H-19), 2.58 (t, 2H,
J= 7.4, H-5), 2.43 (br s, 4H, H-17, H-18), 2.21 (m, 2H, H-
16); Anal. Calcd. for C24H25BrClNO4: C, 56.88; H, 4.97; N,
2.76. Found: C, 56.75; H, 5.07; N, 2.54%.
2.4. General procedure for preparing the derivatives (5a–n)
The substituent piperazine (0.01 mol) was added to a magnet-
ically stirred solution of compound 3 and anhydrous K2CO3 in
dry DMF (25 ml). The reaction mixture was heated at 80 C
for 6–8 h and monitored by TLC. The resulting solid was
212 B. Mistry et al.filtered at room temperature and subjected to anion exchange
into a chloride form. The crude product was chromatographed
on an Al2O3 column and eluted with CHCl3/CH3OH (9:1, v/v)
to give the proposed compound.
2.4.1. 9-O-3-(1-(2-Aminobenzthaizole)pentylberberine (5a)
Light yellow solid, Yield: 65%. m.p. 256–258 C. IR (KBr)
cm1: 3408, 3028, 1641, 1529, 1448, 1102–1075; 1H NMR
(CDCl3, 500 MHz): d 9.81 (s, 1H, H-8), 8.52 (s,1H, H-13),
8.31 (s, 1H, –NH), 7.96 (s, 1H, H-1), 7.77 (d, J= 1.9 Hz,
1H, benzothiazole ring), 7.60–7.51 (m, 3H, benzothiazole
ring), 7.47 (s, 1H, H-12), 7.24 (s, 1H, H-4), 6.80 (s, 1H,
H-11), 6.00 (s, 2H, –OCH2O), 5.02 (t, 2H, J= 6.4, H-6),
4.36 (t, 2H, J= 6.6, H-15), 4.07 (s, 3H, OCH3), 3.12 (t, 2H,
J= 6.5, H-19), 2.54 (t, 2H, J= 7.5, H-5), 2.34 (br s, 4H, H-
17, H-18), 2.09 (m, 2H, H-16); 13C NMR (CDCl3,
500 MHz): d 161.3, 154.1, 152.2, 150.9, 147.4, 144.5, 142.0,
137.6, 135.7, 133.8, 129.3, 127.1, 126.0, 124.9, 123.2,
122.1, 119.2, 117.4, 115.5, 113.0, 109.1, 106.2, 103.3, 72.4,
60.5, 57.6, 54.7, 29.8, 28.9, 25.1, 23.2; Anal. Calcd. for
C31H30ClN3O4S: C, 64.63; H, 5.25; N, 7.29. Found: C,
64.51; H, 5.17; N, 7.40.
2.4.2. 9-O-3-(1-(6-Nitro-2-aminobenzthaizole)pentylberberine
(5b)
Light yellow solid, Yield: 67%. m.p. 261–263 C. IR (KBr)
cm1: 3417, 3025, 1624, 1578, 1512, 1109–1084; 1H NMR
(CDCl3, 500 MHz): d 9.70 (s, 1H, H-8), 8.61 (s,1H, H-13),
8.42 (s, 1H, –NH), 7.86 (s, 1H, H-1), 7.82 (d, J= 1.8 Hz,
1H, benzothiazole ring), 7.67–7.58 (m, 2H, benzothiazole
ring), 7.54 (s, 1H, H-12), 7.39 (s, 1H, H-4), 6.69 (s, 1H,
H-11), 6.05 (s, 2H, –OCH2O), 4.93 (t, 2H, J= 6.5, H-6),
4.25 (t, 2H, J= 6.4, H-15), 4.12 (s, 3H, OCH3), 3.23 (t, 2H,
J= 6.6, H-19), 2.59 (t, 2H, J= 7.4, H-5), 2.43 (br s, 4H,
H-17, H-18), 2.14 (m, 2H, H-16); 13C NMR (CDCl3,
500 MHz): d 162.8, 155.2, 153.1, 151.0, 148.3, 145.4, 143.5,
138.7, 136.9, 134.0, 130.8, 128.2, 126.2, 124.7, 122.5,
121.9, 120.1, 118.3, 116.4, 114.5, 110.0, 105.9, 104.2, 73.1,
61.6, 58.2, 55.8, 30.5, 28.7, 26.8, 23.4; Anal. Calcd. for
C31H29ClN4O6S: C, 59.95; H, 4.71; N, 9.02. Found: C,
59.83; H, 4.84; N, 9.13.
2.4.3. 9-O-3-(1-(2-Aminobenzothiazole-6-carboxylic acid)
pentylberberine (5c)
Light yellow solid, Yield: 59%. m.p. 249–251 C. IR (KBr)
cm1: 3461, 3074, 1747, 1652, 1534, 1453, 1112–1091; 1H
NMR (CDCl3, 500 MHz): d 11.39 (s, 1H, –OH), 9.76 (s, 1H,
H-8), 8.57 (s,1H, H-13), 8.36 (s, 1H, –NH), 7.91 (s, 1H, H-
1), 7.72 (d, J= 1.7 Hz, 1H, benzothiazole ring), 7.61–7.50
(m, 2H, benzothiazole ring), 7.41 (s, 1H, H-12), 7.29 (s, 1H,
H-4), 6.75 (s, 1H, H-11), 5.95 (s, 2H, –OCH2O), 4.98 (t, 2H,
J= 6.3, H-6), 4.31 (t, 2H, J= 6.5, H-15), 4.03 (s, 3H,
OCH3), 3.18 (t, 2H, J= 6.4, H-19), 2.48 (t, 2H, J= 7.6, H-
5), 2.39 (br s, 4H, H-17, H-18), 2.19 (m, 2H, H-16); 13C
NMR (CDCl3, 500 MHz): d 168.6, 161.5, 154.3, 152.4, 150.7,
147.6, 144.9, 142.2, 138.5, 136.3, 133.6, 129.5, 128.3, 126.9,
125.5, 123.4, 122.3, 119.4, 117.6, 116.9, 113.2, 109.3, 106.4,
103.5, 72.6, 60.7, 57.8, 54.9, 29.1, 27.2, 25.3, 24.1; Anal. Calcd.
for C32H30ClN3O6S: C, 61.98; H, 4.88; N, 6.78. Found: C,
61.86; H, 4.96; N, 6.65.2.4.4. 9-O-3-(1-(6-Methyl-2-aminobenzthaizole)
pentylberberine (5d)
Light yellow solid, Yield: 57%. m.p. 247–249 C. IR (KBr)
cm1: 3368, 3066, 2939, 1634, 1547, 1461, 1105–1076; 1H
NMR (CDCl3, 500 MHz): d 9.82 (s, 1H, H-8), 8.53 (s, 1H,
H-13), 8.32 (s, 1H, –NH), 7.95 (s, 1H, H-1), 7.76 (d,
J= 1.8 Hz, 1H, benzothiazole ring), 7.64–7.55 (m, 2H, ben-
zothiazole ring), 7.52 (s, 1H, H-12), 7.25 (s, 1H, H-4), 6.81
(s, 1H, H-11), 6.01 (s, 2H, –OCH2O), 5.03 (t, 2H, J= 6.3,
H-6), 4.37 (t, 2H, J= 6.5, H-15), 4.08 (s, 3H, OCH3),
3.13 (t, 2H, J= 6.4, H-19), 2.55 (t, 2H, J= 7.6, H-5),
2.35 (br s, 4H, H-17, H-18), 2.10 (m, 2H, H-16), 1.92 (s,
3H, Ar-CH3);
13C NMR (CDCl3, 500 MHz): d 162.4,
155.4, 153.3, 151.2, 148.5, 145.6, 143.7, 137.8, 135.1, 134.1,
130.4, 127.4, 125.6, 124.1, 123.8, 121.2, 120.3, 118.5, 115.6,
114.7, 110.8, 105.7, 104.4, 73.3, 61.2, 58.4, 55.4, 30.7,
27.4, 26.6, 24.2, 20.8; Anal. Calcd. for C32H32ClN3O4S:
C, 65.13; H, 5.47; N, 7.12. Found: C, 65.23; H, 5.56;
N, 7.25.2.4.5. 9-O-3-(1-(6-Methoxy-2-aminobenzthaizole)
pentylberberine (5e)
Light yellow solid, Yield: 58%. m.p. 253–255 C. IR (KBr)
cm1: 3385, 3058, 2946, 1629, 1553, 1456, 1107–1088; 1H
NMR (CDCl3, 500 MHz): d 9.71 (s, 1H, H-8), 8.62 (s,1H,
H-13), 8.43 (s, 1H, –NH), 7.85 (s, 1H, H-1), 7.81 (d,
J= 1.7 Hz, 1H, benzothiazole ring), 7.62–7.54 (m, 2H, ben-
zothiazole ring), 7.46 (s, 1H, H-12), 7.38 (s, 1H, H-4), 6.70
(s, 1H, H-11), 6.06 (s, 2H, –OCH2O), 4.94 (t, 2H, J= 6.4,
H-6), 4.26 (t, 2H, J= 6.6, H-15), 4.13 (s, 3H, OCH3), 3.92
(s, 3H), 3.24 (t, 2H, J= 6.5, H-19), 2.60 (t, 2H, J= 7.4,
H-5), 2.44 (br s, 4H, H-17, H-18), 2.15 (m, 2H, H-16);
13C NMR (CDCl3, 500 MHz): d 161.7, 154.5, 152.6,
150.5, 148.9, 144.7, 142.4, 137.4, 135.5, 133.4, 129.7,
127.5, 126.4, 125.3, 123.1, 121.7, 119.6, 118.9, 115.7,
113.4, 109.5, 106.6, 103.7, 73.5, 60.9, 57.1, 56.7, 54.3,
30.9, 28.5, 25.5, 23.6; Anal. Calcd. for C32H32ClN3O5S:
C, 63.41; H, 5.32; N, 6.93. Found: C, 63.52; H, 5.40; N,
6.81.2.4.6. 9-O-3-(1-(6-Ethoxya-2-minobenzthaizole)
pentylberberine (5f)
Light yellow solid, Yield: 55%. m.p. 266–268 C. IR (KBr)
cm1: 3374, 3081, 2928, 1643, 1545, 1451, 1114–1093; 1H
NMR (CDCl3, 500 MHz): d 9.77 (s, 1H, H-8), 8.58 (s, 1H,
H-13), 8.37 (s, 1H, –NH), 7.90 (s, 1H, H-1), 7.71 (d,
J= 1.9 Hz, 1H, benzothiazole ring), 7.66–7.52 (m, 2H, ben-
zothiazole ring), 7.43 (s, 1H, H-12), 7.27 (s, 1H, H-4), 6.76
(s, 1H, H-11), 5.96 (s, 2H, –OCH2O), 4.99 (t, 2H, J= 6.5,
H-6), 4.32 (t, 2H, J= 6.4, H-15), 4.04 (s, 3H, OCH3),
4.02 (m, 2H), 3.19 (t, 2H, J= 6.6, H-19), 2.49 (t, 2H,
J= 7.5, H-5), 2.40 (br s, 4H, H-17, H-18), 2.20 (m, 2H,
H-16), 1.83 (s, 3H); 13C NMR (CDCl3, 500 MHz): d
162.2, 155.6, 153.5, 151.6, 147.8, 145.2, 143.9, 138.1, 136.7,
134.5, 130.2, 128.6, 126.7, 124.5, 122.6, 121.6, 120.5, 117.8,
116.2, 114.9, 110.6, 106.8, 104.6, 72.8, 67.5, 61.7, 57.3,
55.2, 29.3, 28.3, 26.4, 23.8, 19.2; Anal. Calcd. for C33H34-
ClN3O5S: C, 63.91; H, 5.53; N, 6.78. Found: C, 63.79; H,
5.44; N, 6.67.
Bioactive berberine-benzothiazole moieties 2132.4.7. 9-O-3-(1-(6-Chloro-2-aminobenzthaizole)pentylberberine
(5g)
Light yellow solid, Yield: 60%. m.p. 269–271 C. IR (KBr)
cm1: 3451, 3045, 1656, 1539, 1449, 1106–1079, 769; 1H
NMR (CDCl3, 500 MHz): d 9.83 (s, 1H, H-8), 8.54 (s, 1H, H-
13), 8.33 (s, 1H, –NH), 7.94 (s, 1H, H-1), 7.75 (d, J= 1.9 Hz,
1H, benzothiazole ring), 7.63–7.54 (m, 2H, benzothiazole ring),
7.51 (s, 1H, H-12), 7.26 (s, 1H, H-4), 6.82 (s, 1H, H-11), 6.02 (s,
2H, –OCH2O), 5.04 (t, 2H, J= 6.5, H-6), 4.38 (t, 2H, J= 6.4,
H-15), 4.09 (s, 3H, OCH3), 3.14 (t, 2H, J= 6.6, H-19), 2.56 (t,
2H, J= 7.5, H-5), 2.36 (br s, 4H, H-17, H-18), 2.11 (m, 2H, H-
16); 13C NMR (CDCl3, 500 MHz): d 162.6, 155.8, 153.7, 150.3,
147.1, 145.8, 143.1, 138.3, 136.1, 133.2, 129.6, 128.8, 126.5,
125.1, 123.3, 121.5, 119.7, 117.1, 116.8, 113.1, 110.4, 105.5,
103.9, 72.2, 60.3, 58.6, 54.5, 29.7, 27.6, 25.7, 24.3; Anal. Calcd.
for C31H29Cl2N3O4S: C, 60.98; H, 4.79; N, 6.88. Found: C,
61.04; H, 4.86; N, 6.79.
2.4.8. 9-O-3-(1-(6-Bromo-2-aminobenzthaizole)pentylberberine
(5h)
Light yellow solid, Yield: 62%. m.p. 274–276 C. IR (KBr)
cm1: 3446, 3079, 1649, 1537, 1441, 1102–1082; 1H NMR
(CDCl3, 500 MHz): d 9.72 (s, 1H, H-8), 8.63 (s, 1H, H-13),
8.44 (s, 1H, –NH), 7.89 (s, 1H, H-1), 7.80 (d, J= 1.8 Hz, 1H,
benzothiazole ring), 7.65–7.53 (m, 2H, benzothiazole ring),
7.44 (s, 1H, H-12), 7.37 (s, 1H, H-4), 6.71 (s, 1H, H-11), 6.07
(s, 2H, –OCH2O), 4.95 (t, 2H, J= 6.3, H-6), 4.27 (t, 2H,
J= 6.5, H-15), 4.14 (s, 3H, OCH3), 3.25 (t, 2H, J= 6.4, H-
19), 2.61 (t, 2H, J= 7.6, H-5), 2.45 (br s, 4H, H-17, H-18),
2.16 (m, 2H, H-16); 13C NMR (CDCl3, 500 MHz): d 161.9,
154.7, 152.8, 151.8, 148.7, 144.3, 142.6, 137.2, 135.9, 133.9,
130.9, 127.7, 125.7, 124.2, 122.8, 121.6, 120.8, 118.7, 115.3,
114.6, 109.7, 105.2, 104.1, 73.7, 61.9, 58.8, 55.7, 30.8, 27.8,
26.2, 24.5; Anal. Calcd. for C31H29BrClN3O4S: C, 56.84; H,
4.46; N, 6.42. Found: C, 56.72; H, 4.38; N, 6.51.
2.4.9. 9-O-3-(1-(6-Iodo-2-aminobenzthaizole)pentylberberine
(5i)
Light yellow solid, Yield: 56%. m.p. 252–254 C. IR (KBr)
cm1: 3459, 3062, 1639, 1542, 1445, 1115–1094; 1H NMR
(CDCl3, 500 MHz): d 9.78 (s, 1H, H-8), 8.59 (s, 1H, H-13),
8.38 (s, 1H, –NH), 7.89 (s, 1H, H-1), 7.70 (d, J= 1.7 Hz,
1H, benzothiazole ring), 7.60–7.52 (m, 2H, benzothiazole
ring), 7.49 (s, 1H, H-12), 7.23 (s, 1H, H-4), 6.77 (s, 1H, H-
11), 5.97 (s, 2H, –OCH2O), 5.00 (t, 2H, J= 6.4, H-6), 4.33
(t, 2H, J= 6.6, H-15), 4.05 (s, 3H, OCH3), 3.20 (t, 2H,
J= 6.5, H-19), 2.50 (t, 2H, J= 7.4, H-5), 2.41 (br s, 4H, H-
17, H-18), 2.21 (m, 2H, H-16); 13C NMR (CDCl3,
500 MHz): d 161.2, 154.9, 152.1, 150.1, 148.2, 144.1, 142.8,
137.9, 135.3, 133.1, 130.7, 128.9, 126.3, 124.8, 123.6, 122.4,
120.1, 118.2, 116.1, 113.8, 109.9, 106.1, 103.2, 73.6, 60.1,
57.5, 54.1, 30.6, 28.1, 25.9, 23.1; Anal. Calcd. for
C31H29ClIN3O4S: C, 53.04; H, 4.16; N, 5.99. Found: C,
53.15; H, 4.25; N, 6.07.
2.4.10. 9-O-3-(1-(6-Fluoro-2-aminobenzthaizole)
pentylberberine (5j)
Light yellow solid, Yield: 55%. m.p. 260–262 C. IR (KBr)
cm1: 3465, 3067, 1630, 1531, 1450, 1108–1095; 1H NMR
(CDCl3, 500 MHz): d 9.89 (s, 1H, H-8), 8.55 (s, 1H, H-13),8.34 (s, 1H, –NH), 7.93 (s, 1H, H-1), 7.74 (d, J= 1.8 Hz,
1H, benzothiazole ring), 7.67–7.59 (m, 2H, benzothiazole
ring), 7.53 (s, 1H, H-12), 7.28 (s, 1H, H-4), 6.83 (s, 1H, H-
11), 6.03 (s, 2H, –OCH2O), 5.05 (t, 2H, J= 6.4, H-6), 4.39
(t, 2H, J= 6.6, H-15), 4.10 (s, 3H, OCH3), 3.15 (t, 2H,
J= 6.5, H-19), 2.57 (t, 2H, J= 7.4, H-5), 2.37 (br s, 4H,
H-17, H-18), 2.12 (m, 2H, H-16); 13C NMR (CDCl3,
500 MHz): d 162.1, 155.1, 153.9, 151.7, 147.3, 145.9, 142.5,
138.2, 136.5, 134.7, 129.1, 127.2, 125.9, 125.2, 123.5,
121.1, 119.9, 117.3, 115.9, 114.5, 110.1, 106.3, 104.3,
72.9, 61.5, 57.7, 55.3, 29.9, 27.1, 26.7, 24.7; Anal. Calcd. for
C31H29ClFN3O4S: C, 62.67; H, 4.92; N, 7.07. Found: C,
62.56; H, 4.84; N, 7.16.
2.4.11. 9-O-3-(1-(4, 6-Difluoro-2-aminobenzthaizole)
pentylberberine (5k)
Light yellow solid, Yield: 58%. m.p. 284–286 C. IR (KBr)
cm1: 3435, 3085, 1637, 1528, 1463, 1111–1085; 1H NMR
(CDCl3, 500 MHz): d 9.73 (s, 1H, H-8), 8.64 (s, 1H, H-13),
8.45 (s, 1H, –NH), 7.98 (s, 1H, H-1), 7.79 (d, J= 1.9 Hz,
1H, benzothiazole ring), 7.65 (s, 1H, benzothiazole ring),
7.42 (s, 1H, H-12), 7.38 (s, 1H, H-4), 6.72 (s, 1H, H-11), 6.08
(s, 2H, –OCH2O), 4.96 (t, 2H, J= 6.3, H-6), 4.28 (t, 2H,
J= 6.5, H-15), 4.15 (s, 3H, OCH3), 3.26 (t, 2H, J= 6.6, H-
19), 2.62 (t, 2H, J= 7.5, H-5), 2.46 (br s, 4H, H-17, H-18),
2.17 (m, 2H, H-16); 13C NMR (CDCl3, 500 MHz): d 161.4,
155.3, 153.2, 150.8, 148.4, 145.5, 143.2, 137.7, 135.0, 133.3,
129.4, 128.3, 126.6, 125.4, 123.9, 122.2, 119.2, 118.4, 116.5,
113.2, 110.3, 105.4, 103.8, 73.2, 60.8, 58.1, 54.8, 30.4, 28.0,
25.8, 23.5; Anal. Calcd. for C31H28ClF2N3O4S: C, 60.83; H,
4.61; N, 6.87. Found: C, 60.94; H, 4.54; N, 6.96.
2.4.12. 9-O-3-(1-(6-Trifluoromethyl-2-aminobenzthaizole)
pentylberberine (5l)
Light yellow solid, Yield: 57%. m.p. 273–275 C. IR (KBr)
cm1: 3470, 1625, 1583, 1478, 1427, 1174, 1129, 1106–1096
(C–O–C); 1H NMR (CDCl3, 500 MHz): d 9.79 (s, 1H, H-8),
8.60 (s, 1H, H-13), 8.39 (s, 1H, –NH), 7.88 (s, 1H, H-1), 7.69
(d, J= 1.8 Hz, 1H, benzothiazole ring), 7.64–7.56 (m, 2H,
benzothiazole ring), 7.50 (s, 1H, H-12), 7.30 (s, 1H, H-4),
6.78 (s, 1H, H-11), 5.98 (s, 2H, –OCH2O), 5.01 (t, 2H,
J= 6.5, H-6), 4.34 (t, 2H, J= 6.4, H-15), 4.06 (s, 3H,
OCH3), 3.21 (t, 2H, J= 6.4, H-19), 2.51 (t, 2H, J= 7.6, H-
5), 2.42 (br s, 4H, H-17, H-18), 2.22 (m, 2H, H-16); 13C
NMR (CDCl3, 500 MHz): d 162.3, 154.6, 152.5, 151.5, 147.5,
144.8, 142.1, 138.4, 135.8, 134.2, 130.3, 127.6, 126.1, 125.3,
124.6, 122.7, 121.8, 120.5, 117.5, 115.8, 114.1, 109.0, 106.5,
104.5, 72.7, 61.3, 58.5, 55.1, 29.5, 28.8, 26.5, 24.9; Anal. Calcd.
for C32H29ClF3N3O4S: C, 59.67; H, 4.54; N, 6.52. Found: C,
59.55; H, 4.49; N, 6.43.
2.4.13. 9-O-3-(1-(6-Cyno-2-aminobenzthaizole)pentylberberine
(5m)
Light yellow solid, Yield: 54%. m.p. 280–282 C. IR (KBr)
cm1: 3475, 2278, 1633, 1588, 1485, 1436, 1163, 1132, 1104–
1089 (C–O–C); 1H NMR (CDCl3, 500 MHz): d 9.85 (s, 1H,
H-8), 8.56 (s, 1H, H-13), 8.35 (s, 1H, –NH), 7.92 (s, 1H, H-
1), 7.73 (d, J= 1.8 Hz, 1H, benzothiazole ring), 7.62–7.55
(m, 2H, benzothiazole ring), 7.47 (s, 1H, H-12), 7.37 (s, 1H,
H-4), 6.84 (s, 1H, H-11), 6.04 (s, 2H, –OCH2O), 5.06 (t, 2H,
J= 6.4, H-6), 4.40 (t, 2H, J= 6.6, H-15), 4.11 (s, 3H,
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2.38 (br s, 4H, H-17, H-18), 2.13 (m, 2H, H-16); 13C NMR
(CDCl3, 500 MHz): d 161.6, 155.5, 152.7, 150.4, 148.8, 145.3,
143.8, 137.5, 136.6, 133.5, 130.6, 128.5, 126.8, 124.4, 123.0,
122.4, 120.5, 119.7, 117.8, 116.3, 113.8, 110.5, 105.6, 103.4,
73.8, 60.2, 57.9, 54.0, 30.2, 27.7, 25.6, 23.7; Anal. Calcd. for
C32H29ClN4O4S: C, 63.93; H, 4.86; N, 9.32. Found: C,
63.85; H, 4.78; N, 9.46.2.4.14. 9-O-3-(1-(2-Hydrazinobenzthaizole)pentylberberine
(5n)
Light yellow solid, Yield: 58%. m.p. 271–273 C. IR (KBr)
cm1: 3468, 1631, 1591, 1473, 1429, 1171, 1114–1081 (C–
O–C); 1H NMR (CDCl3, 500 MHz): d 9.74 (s, 1H, H-8),
8.65 (s, 1H, H-13), 8.46 (s, 1H, –NH), 8.29 (s, 1H, –NH),
7.97 (s, 1H, H-1), 7.78 (d, J= 1.7 Hz, 1H, benzothiazole
ring), 7.66–7.53 (m, 3H, benzothiazole ring), 7.44 (s, 1H,
H-12), 7.31 (s, 1H, H-4), 6.73 (s, 1H, H-11), 6.09 (s, 2H,
–OCH2O), 4.97 (t, 2H, J= 6.3, H-6), 4.29 (t, 2H, J= 6.5,
H-15), 4.16 (s, 3H, OCH3), 3.27 (t, 2H, J= 6.6, H-19),
2.63 (t, 2H, J= 7.4, H-5), 2.47 (br s, 4H, H-17, H-18),
2.18 (m, 2H, H-16); 13C NMR (CDCl3, 500 MHz): d
162.5, 154.8, 153.4, 151.1, 147.7, 144.6, 143.4, 138.6, 135.2,
134.6, 129.5, 127.8, 125.8, 125.0, 122.9, 121.3, 120.4, 117.7,
115.6, 114.4, 109.2, 106.7, 104.9, 72.3, 61.1, 58.7, 55.8,
29.6, 28.2, 26.3, 24.1; Anal. Calcd. for C31H31ClN4O4S:
C, 62.99; H, 5.29; N, 9.48. Found: C, 62.88; H, 5.38; N,
9.60.2.5. DPPH free radical scavenging assay
Reduction of the stable 2,2-diphenyl-1-picrylhydrazyl free
radical is the basis of the DPPH antioxidant bioassay. This
compound has an odd electron that exerts a maximum
absorption band of 517 nm (deep violet color) in ethanol.
Substances donate a hydrogen atom when mixed with
DPPH thereby introducing the reduced diphenyl picrylhy-
drazine (non-radical) congener and loss of the violet color.
The results of the DPPH bioassay are presented as a per-
centage of radical scavenging antioxidant activity (RSA%)
of each substance. DPPH radical scavenging activity of the
berberine derivatives 5a–n were determined according to a
method described previously [22,23]. The berberine
derivatives (20 lL) were added to a 96-well microplate with
180 lL of DPPH. Methanol (20 lL) was used as the blank
and optical density was determined at 517 nm after a
30 min incubation. The control contained all reagents except
the scavenger. The DPPH radical scavenging activity of
ascorbic acid was assayed for comparison, and all tests
were performed in triplicate. The RSA% results were
determined according to Mensor et al. [26] as described in
the equation:
%Scavenging¼ Absorbance of blankAbsorbance oftest
Absorbance of blank
 100
A plot of concentration of test compounds and% scaveng-
ing introduced IC50s in the presence of an Ascorbic acid as
standard.2.6. ABTS radical scavenging assay
The ABTS+ radical cation scavenging efficacies of the test
compounds were determined according to a method described
earlier [23,24]. In brief, 20 lL of sample was combined with
180 lL of ABTS radical solution followed by a 10 min incuba-
tion in the dark, and absorbance was measured at 734 nm.
Ascorbic acid was used as a reference. The UV absorption data
represented the radical scavenging rates and the corresponding
IC50s for the test compounds.
The scavenging capability of the ABTS+ radical was calcu-
lated using the following equation:
%Scavenging¼Absorbance of blankAbsorbance of test
Absorbance of blank
 1002.7. In vitro anticancer bioassay
2.7.1. Cell cultures
Test compounds 5a–n were checked for their in vitro anticancer
activities against the HeLa and CaSki cervical cancer cell lines,
SK-OV-3 ovarian cancer cell lines and Madin–Darby canine
kidney (MDCK) cells (American Type Culture Collection,
Manassas, VA, USA). All cells were maintained in a humidi-
fied incubator in 5% CO2 at 32 C. Dulbecco’s Modified
Eagle’s Medium (DMEM) and RPMI-1640 medium
supplemented with 10% of fetal bovine serum (FBS) and 1%
Antibiotic–Antimycotic Solution (100X) were used. DMEM,
RPMI-1640, trypsin-EDTA, Antibiotic–Antimycotic Solution,
and FBS were purchased from Welgene (Daegu, Republic of
Korea).
The cells (2  104 cells/well) were seeded in 96-well plates
and allowed to grow for 1 day. Then, the 96-well plates were
washed twice with phosphate buffer saline (PBS). Aliquots of
0.1, 1, 10, and 100 lL of the test compounds were added to
the plates in triplicate and incubated for 48 h. After incuba-
tion, the medium was removed, and the cells were washed
twice with PBS. Then, 70% acetone was added to fix the cells
and incubated for 1 h at 4 C. After the incubation, the solvent
was removed, and the plates were dried in an oven at 60 C.
The dried plates were incubated overnight in 100 lL SRB
(0.4 mg/L). Then, the SRB was removed, the plates were
washed three times with 1% acetic acid, and dried again at
60 C. Microscopic observations were carried out to determine
cell morphology. The SRB was dissolved with 10 mM Tris
base and incubated overnight. [23,25] Spectrophotometric data
were recorded at 510 nm to calculate the IC50, and the 50%
cytotoxic concentration (CC50).
3. Results and discussion
3.1. Chemistry
Scheme 1 reveals the synthesis of the final berberine–benzoth-
iazole derivatives (5a–n). Demethylation of berberine chloride
under vacuum at 190 C and 20–30 mm Hg pressure
provided an 85% berberrubine (2) yield [26]. Treatment of
1,5-dibromopentane [27] with berberrubine (2) produced the
final intermediate derivative 3 to carry out a nucleophilic
replacement with a variety of heterocyclic compounds that
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Scheme 1 Synthesis of benzothiazole linked berberine derivatives.
Bioactive berberine-benzothiazole moieties 215replaced the benzothiazole groups (4) to produce the 5a–n
molecules and 2-amino-6-substituted benzothiazoles (4) were
yielded in reasonably good yields by treating corresponding
amines with KSCN in glacial acetic acid in the presence of bro-
mine adopting known preparation method [15,28,29].
Synthesis of the proper structures of compounds 5a–n was
verified using FT-IR, 1H NMR, 13C NMR, and elemental
analysis. The FT-IR absorption bands of 5d at 3066 cm1
and 2939 cm1 verified the existence of C–H and C–C stretch-
ing for aromatics, respectively, whereas the C‚C band of aro-
matics provided groups at 1547 cm1 and 1461 cm1 along
with the appearance of the NH proton at 3368 cm1. TheC–O–C band exhibited an intense absorption band at 1105–
1076 cm1 and bands occurring at 1634 cm1 were allocated
to the –C‚N stretching vibrations of the benzothiazole mole-
cule. Further evidence was obtained from the 1H NMR spec-
trum of compound (5d) proton atoms, which revealed the
presence of expected signals corresponding to berberine ring
singlets at 9.82, 8.53, 7.95, 7.52, 7.25 and 6.81 ppm for the
H-8, H-13, H-1, H-12, H-4, and H-11 protons, respectively.
The presence of signal singlet peaks at 8.32 ppm was attributed
to NH functionalities, and a singlet appeared at 6.01 ppm for
the –OCH2O– protons in the berberine ring. Significant peaks
were observed as a triplet at 5.03 ppm and 2.55 ppm for H-6
Table 1 Screening results of DPPH and ABTS radical
scavenging activity of berberine derivatives (5a–n).
N+
O
O
O
OCH3
Cl-
S
N
H
N
R
No. R aIC50 lg/ml ± SD
bDPPH cABTS
5a H 24.50 ± 1.903 6.755 ± 0.088
5b 6-NO2 23.29 ± 1.436 7.570 ± 0.189
5c 6-COOH 17.12 ± 1.290 5.363 ± 0.101
5d 6-CH3 16.21 ± 1.033 5.403 ± 0.027
5e 6-OCH3 13.03 ± 0.086 5.064 ± 0.072
5f 6-OC2H5 19.48 ± 1.336 5.504 ± 0.129
5g 6-Cl 15.58 ± 0.635 5.629 ± 0.096
5h 6-Br 16.88 ± 1.233 6.042 ± 0.159
5i 6-I 22.34 ± 1.267 6.406 ± 0.243
5j 6-F 18.43 ± 0.534 6.134 ± 0.075
5k 4,6-di F 16.40 ± 0.007 5.947 ± 0.023
5l 6-CF3 17.91 ± 1.019 6.031 ± 0.012
5m 6-CN 14.95 ± 0.355 4.958 ± 0.065
5n – 20.83 ± 0.836 5.625 ± 0.093
Berberine 38.00 ± 1.722 82.90 ± 1.170
Ascorbic acid 12.22 ± 0.106 5.042 ± 0.045
a Antioxidant activities are shown as IC50 values in lg/mL. All
assays were carried out in triplicate, and the results expressed as an
average ± standard deviation.
b DPPH= 2,2-diphenyl-1-picrylhydrazyl.
c ABTS = 2,20-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid.
216 B. Mistry et al.and H-5 of the berberine ring. An alkyl chain proton dropped
at around 4.37 ppm by means of a triplet. In addition, the
triplet signal at 3.13 ppm, the broad singlet at 2.35 ppm, and
the multiplet signals at 2.10 ppm were due to the alkyl chain
protons H-19, H-17, H-18, and H-16, respectively. The proton
atoms from the methoxy functional group resonated at
4.08 ppm. Additionally, a doublet at 7.76 ppm was allocated
to the benzothiazole ring and multiplets were detected at
7.64–7.55 ppm from the remaining two protons of the
benzothiazole ring. The 13C NMR spectra provided further
details than those acquired from the IR and 1H NMR
spectra. All novel compounds produced C, H, and N
values within 0.4% from the theoretical values, which was
acceptable.
3.2. Evaluation of biological activities
3.2.1. Antioxidant activities
The antioxidant activities of the synthesized benzothiazole-
based berberine scaffolds were evaluated using DPPH and
ABTS radical scavenging bioassays and the results are sum-
marized in Table 1. The antioxidant activities of the
benzothiazole-based berberine scaffolds varied considerably
depending on the backbone structure and functional groups
attached to the berberine via the pentyl side chain. Overall,
derivatized berberine exerted increased potency in both
antioxidant bioassays compared to that of the analog parent
berberine itself. Different electron withdrawing functional
groups, such as chloro, fluoro, nitro, and trifluoromethyl,
as well as electron donating functional groups, such as
methyl and methoxy, were present on the piperazine moi-
eties attached to the berberine ring. Overall, highly signifi-
cant antioxidant efficacies were observed for compounds
5a–n compared to those of the parent molecule berberine.
The 5a–n scaffolds had IC50 values of 13.03 ± 0.086–24.50
± 1.903 lg/mL and 4.958 ± 0.065–7.570 ± 0.189 lg/mL in
the DPPH and ABTS bioassays, respectively compared to
those of the berberine (38.00 ± 1.722 and 82.90
± 1.170 lg/mL) and were comparable to that of ascorbic
acid control (12.22 ± 0.106 and 5.042 ± 0.045 lg/mL,
respectively). The efficacies of 5a–n as antioxidant agents
were better in the ABTS than those in the DPPH assay.
These results suggest that varying the substituents attached
to the pentyl side chain on the berberine core played a sig-
nificant role in the overall radical scavenging potencies of
the molecules.
Scaffold 5e bearing the electron-donating methoxy func-
tional group was the most potent, with an IC50 to scavenge
DPPH radicals of 13.03 ± 0.086 lg/mL, compared to ascorbic
acid (12.22 ± 0.106 lg/mL). Furthermore, the presence of
electron withdrawing halogen atoms, such as chlorine (5g)
and bromine (5h), on the C-6 position of the 2-
aminobenzothazole ring attached to the berberine core was
effective for scavenging DPPH radicals, with IC50 values of
15.58 ± 0.635 and 16.88 ± 1.233 lg/mL, respectively. In addi-
tion, the analog with the EWD cyano group (5m) exerted
noticeable DPPH scavenging activity, with an IC50 of 14.95
± 0.355 lg/mL, which was the second most potent derivative
against DPPH tested. The presence of two fluorine atoms
increased DPPH scavenging effects of 5k compared to that
of its mono-substituted scaffold (5j), with IC50 values of16.40 ± 0.007 and 18.43 ± 0.534 lg/mL, respectively. Ana-
logs bearing acidic (5c) and trifluoromethyl (5l) groups pre-
sented IC50 values of nearly 17 lg/mL. In general, all the
final compounds exhibited significantly higher DPPH radical
scavenging activity compared to the IC50 value observed for
the parent berberine molecule (12.22 ± 0.106 lg/mL) in the
DPPH bioassay. Moreover, the compound with the EWD
cyano group (5m) yielded an IC50 of 4.958 ± 0.065 lg/mL in
the ABTS assay which was higher than that of ascorbic acid
(5.042 ± 0.045 lg/mL). Several other derivatives, such as 5c–5g,
with either EWD or ED groups had IC50 values of 5 lg/mL,
which was comparable to ascorbic acid and much better than
berberine against ABTS radicals. In fact, scaffolds bearing ED
groups were more active in both antioxidant assays than
compounds bearing halogen atom(s), except an analog
carrying a cyano group. Overall, all compounds demonstrated
increased scavenging effects against the DPPH and ABTS
radicals compared to that of berberine, whereas other
compounds exhibited similar DPPH and ABTS radical
scavenging activities like that of the ascorbic acid control.
3.2.2. Anticancer activities
Analogs 5a–n were examined for their in vitro anticancer
potencies in HeLa (cervical), CaSki (cervical), and SK-OV-3
(ovarian) cells using the SRB bioassay as shown in
Table 2 Screening results of activity of 5a–n against cervical cancer cell lines.
OCH3
N+
O
O
O
Cl-
S
N
H
N
R
No. R aIC50 lg/ml ± SD
a aIC50 lg/ml ± SD
bCC50 lg/ml ± SD
HeLa CaSki MDCK
5a H 6.409 ± 0.059 6.807 ± 0.277 306.4 ± 0.886
5b 6-NO2 6.082 ± 0.014 6.377 ± 0.440 303.6 ± 0.059
5c 6-COOH 6.198 ± 0.104 6.584 ± 0.306 308.1 ± 0.410
5d 6-CH3 5.985 ± 0.060 6.459 ± 0.069 309.1 ± 0.233
5e 6-OCH3 5.878 ± 0.043 5.974 ± 0.083 339.0 ± 0.412
5g 6-Cl 5.844 ± 0.026 5.876 ± 0.359 333.9 ± 0.624
5h 6-Br 6.087 ± 0.114 6.488 ± 0.262 318.4 ± 1.452
5i 6-I 6.324 ± 0.073 6.724 ± 0.421 304.5 ± 0.924
5j 6-F 6.264 ± 0.265 6.653 ± 0.282 308. 6 ± 0.628
5k 4,6-di F 5.913 ± 0.064 5.661 ± 0.352 314.2 ± 0.663
5l 6-CF3 6.465 ± 0.011 6.771 ± 0.300 321.2 ± 3.275
5m 6-CN 5.474 ± 0.019 5.311 ± 0.164 312.8 ± 1.206
5n – 6.406 ± 0.039 6.882 ± 0.255 307.0 ± 1.425
Berberine 5.700 ± 0.026 5.676 ± 0.137 111.8 ± 0.658
a Anticancer activities are shown as IC50 values in lg/mL. All assays were carried out in triplicate, and the results expressed as an average
± standard deviation.
b CC50 – cytotoxicity concentration of 50%.
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cancer potencies against HeLa, CaSki, and SK-OV-3 cells
based on the activity level observed for parent compound ber-
berine. In fact, benzothiazole substitution via the pentyl
chain revealed similar anticancer activities. The IC50 values
were 5.474 ± 0.019–6.465 ± 0.011 lg/mL and 5.311
± 0.164–6.882 ± 0.255 lg/mL against HeLa and CaSki cells,
respectively compared to that of berberine itself, which had
IC50 values of 5.700 ± 0.026 (HeLa) and 5.676 ± 0.137 lg/
mL (CaSki). Varying the functional groups attached to the
benzothiazole ring led to the changes in anticancer efficacies
of the resulting molecules. Secondly, final compounds 5a-n
exerted tolerable cytotoxic nature with cytotoxicity values
ranging from 303.6 ± 0.059 to 339.0 ± 0.412 lg/mL against
MDCK cell lines.
Similarly, the 5e analog with an electron-donating methoxy
functional group had an IC50 value of 5.878 ± 0.043, a
CC50 value of 339.0 ± 0.412 lg/mL against HeLa cells
and was the most potent molecule compared to that of
berberine (IC50 = 5.700 ± 0.026 lg/mL, CC50 = 111.8 ±
0.658 lg/mL). Moreover, the same compound had an IC50
value of 5.974 ± 0.083 lg/mL against CaSki cells. In contrast,
analogs bearing an EWD halogen atom in the form of chlorine
(5g) had IC50 values of 5.844 ± 0.026 and 5.876 ± 0.359 lg/mL,
respectively against HeLa and CaSki cells. This chlorine
based derivative carried very tolerable cytotoxic nature with
333.9 ± 0.624 lg/mL of CC50 toward non-cancer MDCK cell
line. The scaffold with a cyano functional group (5m) also had
anticancer activity, with IC50 values of 5.474 ± 0.019 and5.311 ± 0.164 lg/mL against HeLa and CaSki cells, respec-
tively, a CC50 value of 312.8 ± 1.206 lg/mL against HeLa
and CaSki cells. This was, in fact, the most potent compound
against CaSki cell lines among all tested in the series when
compared to the IC50 of berberine against CaSki at 5.676
± 0.137 lg/mL. Moreover, analogs with ED methyl group
(5d), EWD bromine atom (5h) as well as with two EWD fluo-
rine atoms (5k) demonstrated 5.985 ± 0.060 lg/mL, 6.087
± 0.114 lg/mL and 5.913 ± 0.064 lg/mL of IC50 levels,
respectively against HeLa cell line. Interestingly, analogs (5k)
exhibited 5.661 ± 0.352 lg/mL of IC50 against CaSki cell line.
These analogs are observed to have good to noticeable effects
against both the cervical cancer cell lines. All the remaining
analogs were still noticed to manage higher anticancer effects
in terms of IC50s observed against HeLa and CaSki at nearby
6 lg/mL when compared to that of berberine at around
5.7 lg/mL. Final compounds 5a-n were observed to yield
moderate level of anticancer effects against ovarian cancer cell
line SK-OV-3. Newly furnished scaffolds exhibited 32.61
± 0.581–55.94 ± 0.890 lg/mL of IC50s against SK-OV-3 cell
line. Similar to results obtained from cervical cancer cell lines,
a compound with EWD cyano functional group (5m) exhibited
the highest level of anticancer effects against SK-OV-3 with
32.61 ± 0.581 lg/mL of IC50 and 312.8 ± 1.206 lg/mL of
CC50s, which was comparable to that of berberine at 24.17
± 1.196 lg/mL of IC50. Moreover, an analog with ED meth-
oxy group (5e) was found to exert 37.52 ± 0.469 lg/mL of
IC50 and 339.0 ± 0.412 lg/mL of CC50 which was almost
equal to that of 5m and thus this compound too can be
Table 3 Screening results of activity of 5a–n against ovarian
cancer cell line.
N+
O
O
O
OCH3
Cl-
S
N
H
N
R
No. R aIC50 lg/ml ± SD
bCC50 lg/ml ± SD
SK-OV-3 MDCK
5a H 55.94 ± 0.890 306.4 ± 0.886
5b 6-NO2 55.50 ± 0.415 303.6 ± 0.059
5c 6-COOH 44.58 ± 1.198 308.1 ± 0.410
5d 6-CH3 47.72 ± 0.334 309.1 ± 0.233
5e 6-OCH3 37.52 ± 0.469 339.0 ± 0.412
5f 6-OC2H5 47.77 ± 1.072 325.9 ± 0.397
5g 6-Cl 44.32 ± 0.303 333.9 ± 0.624
5h 6-Br 50.32 ± 1.170 318.4 ± 1.452
5i 6-I 54.27 ± 0.637 302.8 ± 0.735
5j 6-F 53.46 ± 0.266 308.3 ± 1.271
5k 4,6-di F 52.00 ± 0.603 314.2 ± 0.663
5l 6-CF3 53.72 ± 1.100 321.2 ± 3.275
5m 6-CN 32.61 ± 0.581 312.8 ± 1.206
5n – 52.69 ± 1.060 307.0 ± 1.425
Berberine 24.17 ± 1.196 111.8 ± 0.658
a Anticancer activities are shown as IC50 values in lg/mL. All
assays were carried out in triplicate, and the results expressed as an
average ± standard deviation.
b CC50 – cytotoxicity concentration of 50%.
218 B. Mistry et al.regarded as one of the most potent analogs against SK-OV-3
among all tested. Lastly, a scaffold carrying EWD chlorine
atom (5g) exhibited 44.32 ± 0.303 lg/mL of IC50 and 333.9
± 0.624 lg/mL of CC50 and can be said that it had remarkable
sensitivity against SK-OV-3 cell line. Several remaining
compounds demonstrated nearly 45–55 lg/mL of IC50, for
example, compounds 5c, 5d, 5f, 5h and 5k and were regarded
to have noticeable effects against ovarian cancer cell line
SK-OV-3 because all have yielded reasonable IC50s and
tolerable cytotoxicities when compared to that of berberine.
All the remaining scaffolds are found to express good to
moderate inhibition of SK-OV-3 cell line.
4. Conclusion
In summary, berberine-benzothiazole conjugates were devel-
oped to study their antioxidant and anticancer effects. Com-
pounds bearing methoxy or cyano functional groups were
the most active DPPH and ABTS radical scavengers. In gen-
eral, scaffolds carrying EWD groups were more active in the
antioxidant assay than those with halogen functional groups.
Analogs bearing methyl and cyano functional groups pre-
sented the most significant anticancer effects against the HeLa
and CaSki cervical cancer cell lines and the SK-OV-3 ovarian
cancer cell line. Hence, these results suggest that additionalefforts to modify natural product molecules to achieve better
pharmacological effects are warranted.
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